Cardiac resynchronization therapy complications: Difference between revisions
Jump to navigation
Jump to search
m (Bot: Adding CME Category::Cardiology) |
|||
| (8 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
{{Cardiac resynchronization therapy}} | {{Cardiac resynchronization therapy}} | ||
{{CMG}}; {{AOEIC}}: Bhaskar Purushottam, M.D. [mailto:bpurushottam@gmail.com] | {{CMG}}; {{AOEIC}}: Bhaskar Purushottam, M.D. [mailto:bpurushottam@gmail.com] | ||
==Overview== | ==Overview== | ||
[[Bleeding]], [[infection]] and lead dislodgement are not uncommon complications of cardiac resynchronization therapy. | |||
==Complications== | ==Common Complications== | ||
The | #[[Bleeding]] and [[Hematoma]]s: The incidence in clinical trials is 2.4%; in routine clinical practice, the actual incidence of pocket hematomas is probably higher as the trials only reported those hematomas, which needed surgical intervention. It is important to note that early re-intervention of pocket hematomas is associated with a 15-fold increase in infection<ref name="pmid17724263">{{cite journal| author=Klug D, Balde M, Pavin D, Hidden-Lucet F, Clementy J, Sadoul N et al.| title=Risk factors related to infections of implanted pacemakers and cardioverter-defibrillators: results of a large prospective study. | journal=Circulation | year= 2007 | volume= 116 | issue= 12 | pages= 1349-55 | pmid=17724263 | doi=10.1161/CIRCULATIONAHA.106.678664 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17724263 }} </ref>. | ||
=== | |||
#Infection | #Infection | ||
#[[Lead dislodgement]]. (CRT trials demonstrated a rate verying from 2.9% to 10.6%; the MIRACLE-ICD<ref name="pmid12771115">{{cite journal| author=Young JB, Abraham WT, Smith AL, Leon AR, Lieberman R, Wilkoff B et al.| title=Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial. | journal=JAMA | year= 2003 | volume= 289 | issue= 20 | pages= 2685-94 | pmid=12771115 | doi=10.1001/jama.289.20.2685 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12771115 }} </ref> study demonstrated a higher occurence of lead dislodgement with left ventricular lead than right atrial and right ventricular leads-6.8%, 15 and 0.6% respectively). | #[[Lead dislodgement]]. (CRT trials demonstrated a rate verying from 2.9% to 10.6%; the MIRACLE-ICD<ref name="pmid12771115">{{cite journal| author=Young JB, Abraham WT, Smith AL, Leon AR, Lieberman R, Wilkoff B et al.| title=Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial. | journal=JAMA | year= 2003 | volume= 289 | issue= 20 | pages= 2685-94 | pmid=12771115 | doi=10.1001/jama.289.20.2685 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12771115 }} </ref> study demonstrated a higher occurence of lead dislodgement with left ventricular lead than right atrial and right ventricular leads-6.8%, 15 and 0.6% respectively). | ||
==Rare Complications== | |||
#[[Pneumothorax]] (0.9% in CRT trials, Medicare registry<ref name="pmid16781379">{{cite journal| author=Reynolds MR, Cohen DJ, Kugelmass AD, Brown PP, Becker ER, Culler SD et al.| title=The frequency and incremental cost of major complications among medicare beneficiaries receiving implantable cardioverter-defibrillators. | journal=J Am Coll Cardiol | year= 2006 | volume= 47 | issue= 12 | pages= 2493-7 | pmid=16781379 | doi=10.1016/j.jacc.2006.02.049 | pmc=PMC1800827 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16781379 }} </ref> reported 1.2%), | #[[Pneumothorax]] (0.9% in CRT trials, Medicare registry<ref name="pmid16781379">{{cite journal| author=Reynolds MR, Cohen DJ, Kugelmass AD, Brown PP, Becker ER, Culler SD et al.| title=The frequency and incremental cost of major complications among medicare beneficiaries receiving implantable cardioverter-defibrillators. | journal=J Am Coll Cardiol | year= 2006 | volume= 47 | issue= 12 | pages= 2493-7 | pmid=16781379 | doi=10.1016/j.jacc.2006.02.049 | pmc=PMC1800827 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16781379 }} </ref> reported 1.2%), | ||
#[[Myocardial injury]] | #[[Myocardial injury]] | ||
| Line 19: | Line 17: | ||
#[[Pericardial tamponade]]. | #[[Pericardial tamponade]]. | ||
#Pocket erosion | #Pocket erosion | ||
#Lead fracture | #Lead fracture | ||
#Inappropriate [[phrenic nerve]] stimulation: Given the proximity of the posterior wall of the left ventricle to the [[phrenic nerve]], there remains the risk of inappropriate phrenic nerve stimulation. | #Inappropriate [[phrenic nerve]] stimulation: Given the proximity of the posterior wall of the left ventricle to the [[phrenic nerve]], there remains the risk of inappropriate phrenic nerve stimulation. | ||
==Mortality== | ==Mortality== | ||
For CRT patients, the average in-hospital mortality is 0.3% and the 30 day mortality is 0.7%. Reynolds et al.<ref name="pmid16781379">{{cite journal| author=Reynolds MR, Cohen DJ, Kugelmass AD, Brown PP, Becker ER, Culler SD et al.| title=The frequency and incremental cost of major complications among medicare beneficiaries receiving implantable cardioverter-defibrillators. | journal=J Am Coll Cardiol | year= 2006 | volume= 47 | issue= 12 | pages= 2493-7 | pmid=16781379 | doi=10.1016/j.jacc.2006.02.049 | pmc=PMC1800827 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16781379 }} </ref> showed a 1.1% in-hospital mortality in 30,984 Medicare patients undergoing CRT. This disparity in the in-hospital mortality rates can be explained by the strict inclusion criteria of the trials, where the patients are | For CRT patients, the average in-hospital mortality is 0.3% and the 30 day mortality is 0.7%. Reynolds et al.<ref name="pmid16781379">{{cite journal| author=Reynolds MR, Cohen DJ, Kugelmass AD, Brown PP, Becker ER, Culler SD et al.| title=The frequency and incremental cost of major complications among medicare beneficiaries receiving implantable cardioverter-defibrillators. | journal=J Am Coll Cardiol | year= 2006 | volume= 47 | issue= 12 | pages= 2493-7 | pmid=16781379 | doi=10.1016/j.jacc.2006.02.049 | pmc=PMC1800827 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16781379 }} </ref> showed a 1.1% in-hospital mortality in 30,984 Medicare patients undergoing CRT. This disparity in the in-hospital mortality rates can be explained by the strict inclusion criteria of the trials, where the selected patients are healthier than the unselected patients in clinical practice.<ref name="pmid21867832">{{cite journal| author=van Rees JB, de Bie MK, Thijssen J, Borleffs CJ, Schalij MJ, van Erven L| title=Implantation-related complications of implantable cardioverter-defibrillators and cardiac resynchronization therapy devices a systematic review of randomized clinical trials. | journal=J Am Coll Cardiol | year= 2011 | volume= 58 | issue= 10 | pages= 995-1000 | pmid=21867832 | doi=10.1016/j.jacc.2011.06.007 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21867832}} </ref> | ||
==References== | ==References== | ||
| Line 31: | Line 28: | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
[[CME Category::Cardiology]] | |||
[[Category:Cardiology]] | |||
Latest revision as of 07:19, 15 March 2016
|
Cardiac resynchronization therapy Microchapters |
|
Treatment |
|---|
|
Cardiac resynchronization therapy complications On the Web |
|
American Roentgen Ray Society Images of Cardiac resynchronization therapy complications |
|
Directions to Hospitals Administering Cardiac resynchronization therapy |
|
Risk calculators and risk factors for Cardiac resynchronization therapy complications |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief:: Bhaskar Purushottam, M.D. [2]
Overview
Bleeding, infection and lead dislodgement are not uncommon complications of cardiac resynchronization therapy.
Common Complications
- Bleeding and Hematomas: The incidence in clinical trials is 2.4%; in routine clinical practice, the actual incidence of pocket hematomas is probably higher as the trials only reported those hematomas, which needed surgical intervention. It is important to note that early re-intervention of pocket hematomas is associated with a 15-fold increase in infection[1].
- Infection
- Lead dislodgement. (CRT trials demonstrated a rate verying from 2.9% to 10.6%; the MIRACLE-ICD[2] study demonstrated a higher occurence of lead dislodgement with left ventricular lead than right atrial and right ventricular leads-6.8%, 15 and 0.6% respectively).
Rare Complications
- Pneumothorax (0.9% in CRT trials, Medicare registry[3] reported 1.2%),
- Myocardial injury
- Coronary sinus dissection (1.3%) or perforation (1.3%)(complication rate related to coronary veins has been reported in 2%)
- Pericardial tamponade.
- Pocket erosion
- Lead fracture
- Inappropriate phrenic nerve stimulation: Given the proximity of the posterior wall of the left ventricle to the phrenic nerve, there remains the risk of inappropriate phrenic nerve stimulation.
Mortality
For CRT patients, the average in-hospital mortality is 0.3% and the 30 day mortality is 0.7%. Reynolds et al.[3] showed a 1.1% in-hospital mortality in 30,984 Medicare patients undergoing CRT. This disparity in the in-hospital mortality rates can be explained by the strict inclusion criteria of the trials, where the selected patients are healthier than the unselected patients in clinical practice.[4]
References
- ↑ Klug D, Balde M, Pavin D, Hidden-Lucet F, Clementy J, Sadoul N; et al. (2007). "Risk factors related to infections of implanted pacemakers and cardioverter-defibrillators: results of a large prospective study". Circulation. 116 (12): 1349–55. doi:10.1161/CIRCULATIONAHA.106.678664. PMID 17724263.
- ↑ Young JB, Abraham WT, Smith AL, Leon AR, Lieberman R, Wilkoff B; et al. (2003). "Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial". JAMA. 289 (20): 2685–94. doi:10.1001/jama.289.20.2685. PMID 12771115.
- ↑ 3.0 3.1 Reynolds MR, Cohen DJ, Kugelmass AD, Brown PP, Becker ER, Culler SD; et al. (2006). "The frequency and incremental cost of major complications among medicare beneficiaries receiving implantable cardioverter-defibrillators". J Am Coll Cardiol. 47 (12): 2493–7. doi:10.1016/j.jacc.2006.02.049. PMC 1800827. PMID 16781379.
- ↑ van Rees JB, de Bie MK, Thijssen J, Borleffs CJ, Schalij MJ, van Erven L (2011). "Implantation-related complications of implantable cardioverter-defibrillators and cardiac resynchronization therapy devices a systematic review of randomized clinical trials". J Am Coll Cardiol. 58 (10): 995–1000. doi:10.1016/j.jacc.2011.06.007. PMID 21867832.